Icahn School of Medicine at Mount Sinai at CTAD 2026

Nov 16–19, 2026 Boston, MA ~1.7k attendees Website

Icahn School of Medicine at Mount Sinai takes part in 3 sessions at CTAD 2026 in Boston. Its program pairs blood biomarker reliability with preclinical drug work. Its work covers the reproducibility of commercial plasma tests and intranasal and neurotrophic candidates tested in mouse models.

Organization	CTAD 2026 Attendance
Icahn School of Medicine at Mount Sinai New York, New York
icahn.mssm.edu Universities & institutes Medical school of the Mount Sinai Health System in New York; home of an NIA-funded Alzheimer's Disease Research Center.	Poster Wed Nov 18 7:15am–5:30pm Short-term reproducibility and clinical risk categorization of commercial plasma biomarkers for Alzheimer’s disease in a real-world US hospital setting (P280) Blood and CSF biomarkers Poster Wed Nov 18 7:15am–5:30pm ALC919 employs neurotrophic, glymphatic and anti-inflammatory mechanisms to arrest amyloid-β oligomer toxicity and restore brain mitochondrial complex I function (P334) Other mechanisms and targets Poster Wed Nov 18 7:15am–5:30pm Preclinical Validation of VGF-Derived Peptide TLQP-21 as an Intranasal Therapeutic in the 5xFAD Mouse Model of Alzheimer’s Disease (P353) Other mechanisms and targets

Organization

CTAD 2026 Attendance

Icahn School of Medicine at Mount Sinai

New York, New York

icahn.mssm.edu

Universities & institutes

Medical school of the Mount Sinai Health System in New York; home of an NIA-funded Alzheimer's Disease Research Center.

Poster

Wed Nov 18
7:15am–5:30pm

Short-term reproducibility and clinical risk categorization of commercial plasma biomarkers for Alzheimer’s disease in a real-world US hospital setting (P280)

Blood and CSF biomarkers

Poster

Wed Nov 18
7:15am–5:30pm

ALC919 employs neurotrophic, glymphatic and anti-inflammatory mechanisms to arrest amyloid-β oligomer toxicity and restore brain mitochondrial complex I function (P334)

Other mechanisms and targets

Poster

Wed Nov 18
7:15am–5:30pm

Preclinical Validation of VGF-Derived Peptide TLQP-21 as an Intranasal Therapeutic in the 5xFAD Mouse Model of Alzheimer’s Disease (P353)

Other mechanisms and targets

Instantly find 20 buyers from Icahn School of Medicine at Mount Sinai

Get a list of who you should contact, their contact info, and what to say.

Totally free and instant, no sign up necessary!

Not affiliated with or endorsed by the CTAD Conference. Organization details are derived from CTAD’s published program, poster list and sponsor page. Submit a correction